Clinical treatment of malignant hyperthermia in three cases

Pan,Tao; Ji,Wenli; Nie,Mengqi; Li,Yang

doi:10.3892/etm.2016.3712

Clinical treatment of malignant hyperthermia in three cases

Authors:
- Tao Pan
- Wenli Ji
- Mengqi Nie
- Yang Li
View Affiliations

Affiliations: Department of Intensive Care Medicine, Xiangyang Hospital Affiliated to Hubei University of Medicine, Wuhan, Hubei 441000, P.R. China
Published online on: September 16, 2016 https://doi.org/10.3892/etm.2016.3712
Pages: 2881-2884
Copyright: © Pan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant hyperthermia (MH) is a rare life threatening inherited disorder that is triggered by drugs used for general anesthesia in susceptible persons. The symptoms include rapid increase of body temperature and severe muscle contractions. The present study includes 3 cases of MH and highlights the timely identification of symptoms for rescuing the patient. In case I, a 7-year-old male child underwent surgery with ketamine at a dose of 250 mg. After 4 h of operation, the child went through convulsions, high fever and succumbed within a few hours. High fever was not detected in a timely manner, which is one of the main symptoms of MH. In case II, a 12-year-old male child had convulsions and high fever after simple surgery caused by MH. Once confirmed, immediate measures were taken to lower the body temperature and the child was rescued. In case III, a male 57-year-old was admitted to hospital due to paraplegia. The patient underwent more critical conditions once symptoms of MH appeared. Additionally, antidote dantrolene was unavailable in the first and third case; thus, the progression of disease was not alleviated although active symptomatic and supportive treatment were employed.

View Figures

View References

1	Kamińska E, Janas A and Osica P: Malignant hyperthermia - problem in dental surgery. An introductory report. Dev Period Med. 18:483–488. 2014.(In Polish). PubMed/NCBI
2	Riazi S, Kraeva N, Muldoon SM, Dowling J, Ho C, Petre MA, Parness J, Dirksen RT and Rosenberg H: Malignant hyperthermia and the clinical significance of type-1 ryanodine receptor gene (RYR1) variants: proceedings of the 2013 MHAUS Scientific Conference. Can J Anaesth. 61:1040–1049. 2014. View Article : Google Scholar : PubMed/NCBI
3	Roesl C, Sato K, Schiemann A, Pollock N and Stowell KM: Functional characterisation of the R2452W ryanodine receptor variant associated with malignant hyperthermia susceptibility. Cell Calcium. 56:195–201. 2014. View Article : Google Scholar : PubMed/NCBI
4	Han H, Shao J and Zhang M: Diagnosis and treatment of malignant hyperthermia. Chinese General Medical Council. 11:314–317. 2008.(In Chinese).
5	Itoh K, Nishibe S, Usuda Y and Kitamura A: Suspected case of postoperative malignant hyperthermia treated with dantrolene one week after neurosurgery. Masui. 63:1153–1155. 2014.(In Japanese). PubMed/NCBI
6	Wang Y, Guo X and Luo A: Diagnosis and treatment progress of malignant hyperthermia. Chinese J Anesthesiol. 26:92–94. 2006.(In Chinese).
7	Aderibigbe T, Lang BH, Rosenberg H, Chen Q and Li G: Cost-effectiveness analysis of stocking dantrolene in ambulatory surgery centers for the treatment of malignant hyperthermia. Anesthesiology. 120:1333–1338. 2014. View Article : Google Scholar : PubMed/NCBI
8	Brislin RP and Theroux MC: Core myopathies and malignant hyperthermia susceptibility: a review. Paediatr Anaesth. 23:834–841. 2013. View Article : Google Scholar : PubMed/NCBI
9	Nelson P and Litman RS: Malignant hyperthermia in children: an analysis of the North American malignant hyperthermia registry. Anesth Analg. 118:369–374. 2014. View Article : Google Scholar : PubMed/NCBI
10	Hoppe K, Schleip R, Lehmann-Horn F, Jäger H and Klingler W: Contractile elements in muscular fascial tissue - implications for in-vitro contracture testing for malignant hyperthermia. Anaesthesia. 69:1002–1008. 2014. View Article : Google Scholar : PubMed/NCBI
11	Kazantseva AA and Lebedinskiĭ KM: Modern diagnostic approaches to malignant hyperthermia susceptibility. Anesteziol Reanimatol. 59:64–68. 2014.(In Russian). PubMed/NCBI
12	Gillies RL, Bjorksten AR, Du Sart D and Hockey BM: Analysis of the entire ryanodine receptor type 1 and alpha 1 subunit of the dihydropyridine receptor (CACNA1S) coding regions for variants associated with malignant hyperthermia in Australian families. Anaesth Intensive Care. 43:157–166. 2015.PubMed/NCBI
13	Yang Z, Wu X and Huang Z: Retrospective comparative analysis of malignant hyperthermia. Clin Med (Northfield, IL). 30:8–11. 2010.
14	Wang YL, Guo XY and Luo AL: Malignant hyperthermia in Mainland China: an analysis of 34 cases. Chinese Anesthesiol. 26:107–109. 2006.(In Chinese).
15	Larach MG, Brandom BW, Allen GC, Gronert GA and Lehman EB: Cardiac arrests and deaths associated with malignant hyperthermia in North America from 1987 to 2006: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States. Anesthesiology. 108:603–611. 2008. View Article : Google Scholar : PubMed/NCBI
16	Nakamura N, Ueda T, Ishikawa R, Tasaka Y, Fukuuchi K and Sato N: Malignant hyperthermia developing during esophageal resection in an 82-year-old man. J Anesth. 22:464–466. 2008. View Article : Google Scholar : PubMed/NCBI
17	Riazi S, Larach MG, Hu C, Wijeysundera D, Massey C and Kraeva N: Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands. Anesth Analg. 118:381–387. 2014. View Article : Google Scholar : PubMed/NCBI
18	Vigilante JA: Case report: clearance to dive for a naval candidate with family history of malignant hyperthermia. Undersea Hyperb Med. 40:365–369. 2013.PubMed/NCBI
19	Sousa CS and Cunha AL: Knowledge of nursing professionals of a surgical center regarding malignant hyperthermia. Rev Gaucha Enferm. 35:43–48. 2014.(In Portuguese). View Article : Google Scholar
20	Rosero EB, Adesanya AO, Timaran CH and Joshi GP: Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005. Anesthesiology. 110:89–94. 2009. View Article : Google Scholar : PubMed/NCBI
21	Bina S, Capacchione J, Munkhuu B, Muldoon S and Bünger R: Is lymphocyte adenosine a diagnostic marker of clinical malignant hyperthermia? A pilot study. Crit Care Med. 43:584–593. 2015. View Article : Google Scholar : PubMed/NCBI
22	Larach MG, Brandom BW, Allen GC, Gronert GA and Lehman EB: Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007℃2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States. Anesth Analg. 119:1359–1366. 2014. View Article : Google Scholar : PubMed/NCBI
23	Liu Z, Fang L and Teng Y: Clinical diagnosis and treatment of malignant Hyperthermia. J Emerg Med. 16:1226–1227. 2010.
24	Altamirano F, Eltit JM, Robin G, Linares N, Ding X, Pessah IN, Allen PD and López JR: Ca²⁺ influx via the Na⁺/Ca²⁺ exchanger is enhanced in malignant hyperthermia skeletal muscle. J Biol Chem. 289:19180–19190. 2014. View Article : Google Scholar : PubMed/NCBI
25	Cain CL, Riess ML, Gettrust L and Novalija J: Malignant hyperthermia crisis: optimizing patient outcomes through simulation and interdisciplinary collaboration. AORN J:. 99:301–308. 2014. View Article : Google Scholar : PubMed/NCBI
26	Shaaban S, Ramos-Platt L, Gilles FH, Chan WM, Andrews C, De Girolami U, Demer J and Engle EC: RYR1 mutations as a cause of ophthalmoplegia, facial weakness, and malignant hyperthermia. JAMA Ophthalmol. 131:1532–1540. 2013. View Article : Google Scholar : PubMed/NCBI
27	Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van SH, Ronco C and Kellum JA: Continuous renal replacement therapy: A worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. Kidney) investigators. Intensive Care Med. 33:1563–1570. 2007. View Article : Google Scholar : PubMed/NCBI
28	Sheng R, Jiao JJ and Ting W: Research on multiple organ dysfunction syndrome with Ulinastatin and continuous blood purification therapy. J Emerg Med. 17:622–626. 2008.